
Sign up to save your podcasts
Or


Vendor AI demos show real efficiency that never reaches the staffing model. The workflow redesign and oversight cost behind AI value in radiation oncology.
medsolvedynamics.com | [email protected]
#AIinHealthcare #RadiationOncology #WorkflowFit #OncologyOperations
Lutetium-177 has a half-life of about 6.6 days, so a radioligand therapy no-show is a paid dose decaying in your department. The dose economics behind theranostics scheduling and isotope supply.
medsolvedynamics.com | [email protected]
#Theranostics #RadioligandTherapy #IsotopeSupply #OncologyOperations
AI purchasing differs fundamentally from traditional capital and software decisions. The cost is not the license, it is the recurring monitoring as the model drifts in ways no tolerance table catches. From hype to value: how to evaluate AI for long-term cost structure, clinical accountability, and organizational readiness, not the demo.
medsolvedynamics.com | [email protected]
#RadiationOncology #AIinHealthcare #OncologyLeadership #HealthcareAI
In radiation oncology, a curative no-show is a slot you backfill. In theranostics, the Lu-177 dose is a fixed amount with about a five-day shelf life, scheduled for one patient, and it cannot wait for a better day. Here is how scheduling discipline, authorized user coverage, and capture mechanics determine whether a theranostics service line holds its margin, and the two operating costs the vendor proforma leaves out.
medsolvedynamics.com | [email protected]
#Theranostics #RadiationOncology #RadiopharmaceuticalTherapy #OncologyOperations
A society guideline on low-dose radiation for osteoarthritis makes benign disease a real service-line conversation in radiation oncology. Clinical appropriateness and program readiness are different questions. Here is the operational and financial read: the referral pathway, the payer coverage and prior-authorization pathway, and using open LINAC capacity for incremental benign volume without affecting the curative schedule.
medsolvedynamics.com | [email protected]
#RadiationOncology #Osteoarthritis #ServiceLineGrowth #BenignDisease
Most rad onc programs walk into a service contract renewal with no independent numbers on the table. The vendor brings their performance data. The program nods. The renewal runs the vendor's direction. The gap is not in the contract language. It is in the measurement asymmetry. Five metrics the vendor tracks and the program rarely does. Uptime delivered against contracted spec. Response time against contracted SLA. Preventive maintenance hours delivered against contracted hours. Parts coverage against parts billed extra. First-call resolution rate. Pull the data quarterly, reconcile against contract spec, build the quarterly service review around the gap.
medsolvedynamics.com | [email protected]
At ESTRO 2026, United Imaging showed a CE-marked uRT-linac 506c on the show floor. Diagnostic-CT integrated with a linear accelerator on a single platform. Online adaptive radiotherapy positioned without an MR-linac, without a third-party planning system, and without RaySearch. Reported as CE marked in Europe. Not yet in the US market. Capital decisions in flight in the US in 2026 are not changing because of what showed up in Berlin. What changed is the leverage map on every conversation around them.
medsolvedynamics.com | [email protected]
Most rad onc programs sitting on soft Q2 numbers are looking outside the building for offsetting revenue. The infrastructure for radioligand therapy is already inside the building, and a Jefferson-authored paper accepted by Practical Radiation Oncology in May 2026 puts the 340B-eligible hospital gross margin at roughly $101,000 per Pluvicto patient over a full course. The same paper names why programs stall. The rad onc on a dollars-per-wRVU comp model takes a 26-wRVU haircut against EBRT for picking up RPT. The credential map is already in the department. The comp model discussion is in the way. The operator move is to renegotiate the comp model with the 340B margin as the leverage before the service line gets approved.
medsolvedynamics.com | [email protected]
From 20 years on the vendor side of oncology software sales, the one question that exposes the AI price premium baked into software renewal quotes in 2026. Treatment planning systems, contouring software, registry products, SaaS modules. The AI features were priced higher than the same software would have priced two years ago. Get the unbundled price.
medsolvedynamics.com | [email protected]
A vendor-side story Yoel Bakas has watched play out dozens of times in radiation oncology. A software demo runs without anyone asking what is actually broken in the customer's workflow. The tool gets relabeled AI-enabled a year later. Until the customer understands what is broken, it does not matter what the tool is. AI in radiation oncology, workflow design, vendor evaluation, capital decision.
medsolvedynamics.com | [email protected]